Cynata Therapeutics has reached a pivotal moment in its clinical development journey, marking the completion of the 100-day primary evaluation period for all participants in its Phase 2 trial of CYP-001, a stem cell therapy targeting acute graft-versus-host disease. …
Cynata reaches crucial milestone as Phase 2 trial moves toward results
March 30, 2026 Australian Biotech
Latest Video
New Stories
-
Alterity Therapeutics updates investors on key meeting with US regulator
March 30, 2026 - - Australian Biotech -
Aroa Biosurgery reports promising trial milestone for advanced wound treatment
March 30, 2026 - - Australian Biotech -
Genetic Signatures reshapes its business to cut costs and drive growth
March 30, 2026 - -
Cynata reaches crucial milestone as Phase 2 trial moves toward results
March 30, 2026 - - Australian Biotech -
AI meets oncology as Algorae advances drug discovery collaboration
March 30, 2026 - - Australian Biotech -
The minister was subtle, but read between the lines, and the message could hardly be clearer
March 30, 2026 - - Latest News -
Government expands access to cancer therapy but holds short on pan-tumour listing
March 30, 2026 - - Latest News